A phase 3 study of Bardoxolone Methyl 1 (RTA 402) to treat patients with Diabetic Kidney Disease-2 (DKD).

Next Previous
Trial Profile

A phase 3 study of Bardoxolone Methyl 1 (RTA 402) to treat patients with Diabetic Kidney Disease-2 (DKD).

Planning
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Diabetic neuropathies
  • Focus Registrational; Therapeutic Use
  • Sponsors Kyowa Hakko Kirin

    • Most Recent Events

    • 04 Apr 2018 New trial record
    • 28 Mar 2018 According to a Kyowa Hakko Kirin media release, company plans to initiate this study in 2018 in Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top